New Times,
New Thinking.

  1. Business
26 September 2012

Standard Chartered: will it stay independent?

Shares plummet after reports of 18 per cent sale.

By New Statesman

There’s a rumour circling that Standard Chartered will relinquish its status as an independent bank, after reports that 18 per cent of it is up for sale.

The Financial Times reported today that the Singapore investor Temasek could be selling its StanChart shareholding: a £6bn slice. There are no decisions yet, but the report send StanChart shares 2 per cent lower.   

According to financial website thisismoney.com, the report has also brought up talk of a StanChart takeover:

The news has reignited takeover speculation, as it emerged that Santander and US investment bank JP Morgan have expressed interest in the stake.

The FT’s John Gapper was sceptical about any major transformation just yet however:

Select and enter your email address Your weekly guide to the best writing on ideas, politics, books and culture every Saturday. The best way to sign up for The Saturday Read is via saturdayread.substack.com The New Statesman's quick and essential guide to the news and politics of the day. The best way to sign up for Morning Call is via morningcall.substack.com
Visit our privacy Policy for more information about our services, how Progressive Media Investments may use, process and share your personal data, including information on your rights in respect of your personal data and how you can unsubscribe from future marketing communications.
THANK YOU

No doubt Standard Chartered will cease to exist as an independent bank one day, but I have heard speculation about it for 20 years, and it never quite seems to happen. It is like talk of the dollar losing its status as a reserve currency.

The recent dust-up with the New York State banking regulator over dealings with Iran, leading to it paying a $340m fine, was not enough to make it truly vulnerable. Maybe something will occur this time, but – famous last words – I am a sceptic.

Content from our partners
Unlocking investment in UK life sciences through manufacturing
Data defines a new era for fundraising
A prescription for success: improving the UK's access to new medicines